Journal ArticleDOI
Dupilumab as a novel steroid-sparing treatment for IgG4-related disease.
TLDR
It was postulated by the authors to investigate dupilumab as a novel steroid-sparing treatment for IgG4-RD.Abstract:
IgG4-related disease (IgG4-RD) is a rare fibroinflammatory, multisystemic condition with a relapsing-remitting progression.1 The level of serum IgG4 correlates with inflammatory activity and organ involvement.1 Glucocorticoids are first line for IgG4-RD, but there are numerous adverse effects with chronic use.2 Dupilumab is a monoclonal antibody that acts on the interleukin 4 (IL-4) receptor alpha, shared by the IL-4 and IL-13 receptors.1 IL-4 causes isotype switching from IgM to IgG4 and IL-13 is implicated in fibrosis.3 Thus, it was postulated by the authors to investigate dupilumab as a novel steroid-sparing treatment for IgG4-RD.
A 67-year-old man with no known allergies and a history of sensory neural hearing loss, recurrent bronchitis, spinal stenosis, moderate positional obstructive sleep apnoea, asthma, atopic dermatitis (which caused swelling around his eyes) and allergic rhinoconjunctivitis underwent extensive investigations over the past 2 years due to suspected IgG4-RD.
The patient’s initial complaint was pruritic erythematous lesions on the legs, arms, chest and palms. …read more
Citations
More filters
Journal ArticleDOI
Enfermedad relacionada con IgG4
TL;DR: Todos los organos afectados by the ER-IgG4 comparten unas caracteristicas histopatologicas: infiltrado linfoplasmocitario con abundantes celulas plasmaticas IgG4 positivas, fibrosis with un patron estoriforme, flebitis obliterante and presencia of eosinofilos.
Journal ArticleDOI
Pembrolizumab-Associated Expansion of Radiation-Induced Morphea Responsive to Dupilumab: A Case Report.
Jordan T. Said,C Iriarte,Jordan Talia,Bonnie Leung,Cesar A. Virgen,Matthew Robertson,Michael S. Rabin,Cecilia A. Larocca,Nicole R. LeBoeuf +8 more
TL;DR: In this article , the authors report a patient who first received local radiation therapy to the thorax for lung adenocarcinoma that was complicated by radiation-induced morphea (RIM), which progressed widely beyond the irradiated field in the setting of pembrolizumab therapy.
Journal ArticleDOI
Implication of allergy and atopy in IgG4-related disease
TL;DR: In this article , the authors reviewed what is currently known about the allergy and atopy in the context of immunoglobulin G4-related disease (IgG4-RD).
Journal ArticleDOI
Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease-a retrospective investigation of 845 patients and its clinical relevance.
Hung Cheng Tsai,Hung Cheng Tsai,Hsiang Yun Tung,Chih-Wei Liu,Chih-Wei Liu,Chin Fang Su,Chin Fang Su,Yi Syuan Sun,Yi Syuan Sun,Wei Sheng Chen,Wei Sheng Chen,Ming Han Chen,Ming Han Chen,Chien Chih Lai,Chien Chih Lai,Hsien-Tzung Liao,Hsien-Tzung Liao,Ying Ying Yang,Ying Ying Yang,Yi Hsiang Huang,Chang-Youh Tsai,Chang-Youh Tsai +21 more
TL;DR: In this article, the authors investigated the clinical relevance of high serum IgG4 level in non-IgG4-related disease patients and to see if Ig4-RD in Taiwan differs from that in other parts of the world.
Journal ArticleDOI
Immunoglobulin G4-Related ophthalmic disease and aortitis
TL;DR: In this article , a case of IgG4-related disease involving the extraocular muscles and aorta in an elderly male who improved with oral prednisolone was reported.
References
More filters
Journal ArticleDOI
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011
Hisanori Umehara,Kazuichi Okazaki,Yasufumi Masaki,Mitsuhiro Kawano,Motohisa Yamamoto,Takako Saeki,Shoko Matsui,Tadashi Yoshino,Shigeo Nakamura,Shigeyuki Kawa,Hideaki Hamano,Terumi Kamisawa,Toru Shimosegawa,Akira Shimatsu,Seiji Nakamura,Tetsuhide Ito,Kenji Notohara,Takayuki Sumida,Yoshiya Tanaka,Tsuneyo Mimori,Tsutomu Chiba,Michiaki Mishima,Toshifumi Hibi,Hirohito Tsubouchi,Kazuo Inui,Hirotaka Ohara +25 more
TL;DR: The comprehensive diagnostic criteria for IgG4-RD are practically useful for general physicians and nonspecialists and have increased the sensitivity of diagnosis to 100% for Igg4-related MD, KD, and AIP.
Journal ArticleDOI
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt,Marjolein S. de Bruin-Weller,Melinda Gooderham,Jennifer Clay Cather,Jamie Weisman,David M. Pariser,Eric L. Simpson,Kim A. Papp,H. Chih ho Hong,Diana Rubel,Peter Foley,Errol P. Prens,Christopher E.M. Griffiths,Takafumi Etoh,Pedro Herranz Pinto,Ramon M. Pujol,Jacek C Szepietowski,Karel Ettler,Lajos Kemény,Xiaoping Zhu,Bolanle Akinlade,Thomas Hultsch,Vera Mastey,Abhijit Gadkari,Laurent Eckert,Nikhil Amin,Neil M.H. Graham,Gianluca Pirozzi,Neil Stahl,George D. Yancopoulos,Brad Shumel +30 more
TL;DR: This 1-year, randomised, double-blinded, placebo-controlled, phase 3 study aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical cortiosteroids in adults with moderate-to-severe atopic dermatitis.
Journal ArticleDOI
IgG4-related disease
TL;DR: Identification of specific antigens and T-cell clones that drive the disease will be the first steps to elucidate the pathogenesis of IgG4-related disease.
Journal ArticleDOI
Commonality of the IL-4/IL-13 pathway in atopic diseases
TL;DR: Dupilumab, a human monoclonal antibody that simultaneously inhibits signaling of IL-4 and IL-13, has demonstrated significant clinical efficacy in AD, asthma, and CSwNP, suggesting that there is a common underlying pathogenic pathway, and that IL- 4 and IL -13 cytokines are central to regulating the pathogenesis of these atopic diseases.
Journal ArticleDOI
Rituximab and immune deficiency: case series and review of the literature.
Blanka Kaplan,Blanka Kaplan,Blanka Kaplan,Yelena Kopyltsova,Amrita Khokhar,Amrita Khokhar,Fung Lam,Vincent R. Bonagura +7 more
TL;DR: There are patients with persistent B-cell dysfunction long after rituximab treatment was discontinued, and these patients should be distinguished from patients with primary immunodeficiency diseases.
Related Papers (5)
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
Zachary S. Wallace,Ray Naden,Suresh T. Chari,Hyon K. Choi,Emanuel Della-Torre,Jean Francois Dicaire,Phillip A. Hart,Dai Inoue,Mitsuhiro Kawano,Arezou Khosroshahi,Marco Lanzillotta,Kazuichi Okazaki,Cory A. Perugino,Amita Sharma,Takako Saeki,Nicolas Schleinitz,Naoki Takahashi,Hisanori Umehara,Yoh Zen,John H. Stone +19 more
International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease
Arezou Khosroshahi,Zachary S. Wallace,J. L. Crowe,Takashi Akamizu,Atsushi Azumi,M. N. Carruthers,Suresh T. Chari,Emanuel Della-Torre,Luca Frulloni,Hiroshi Goto,Phil A. Hart,Terumi Kamisawa,Shigeyuki Kawa,Mitsuhiro Kawano,Myung-Hwan Kim,Yuzo Kodama,Kensuke Kubota,Markus M. Lerch,Matthias Löhr,Yasufumi Masaki,Shoko Matsui,Tsuneyo Mimori,Seiji Nakamura,Takahiro Nakazawa,Hirotaka Ohara,Kazuichi Okazaki,Jay H. Ryu,Takako Saeki,Nicolas Schleinitz,Akira Shimatsu,Toru Shimosegawa,Hiroki Takahashi,Masayuki Takahira,Atsushi Tanaka,Mark Topazian,Hisanori Umehara,George J. Webster,Thomas E. Witzig,Motohisa Yamamoto,W. Zhang,Tsutomu Chiba,John H. Stone +41 more